Equities Analysts Issue Forecasts for Gritstone bio, Inc.’s Q1 2024 Earnings (NASDAQ:GRTS)

Gritstone bio, Inc. (NASDAQ:GRTSFree Report) – Equities researchers at B. Riley issued their Q1 2024 earnings estimates for Gritstone bio in a report released on Tuesday, April 16th. B. Riley analyst M. Mamtani expects that the company will post earnings per share of ($0.23) for the quarter. The consensus estimate for Gritstone bio’s current full-year earnings is ($0.91) per share. B. Riley also issued estimates for Gritstone bio’s Q4 2024 earnings at ($0.16) EPS and FY2024 earnings at ($0.80) EPS.

Several other equities research analysts also recently weighed in on the stock. JMP Securities raised their target price on shares of Gritstone bio from $4.00 to $5.00 and gave the company a “market outperform” rating in a research note on Tuesday, April 2nd. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Gritstone bio in a research note on Wednesday, March 6th.

View Our Latest Report on GRTS

Gritstone bio Price Performance

Shares of GRTS opened at $0.75 on Thursday. The company has a market cap of $73.08 million, a price-to-earnings ratio of -0.62 and a beta of 0.38. Gritstone bio has a twelve month low of $0.67 and a twelve month high of $3.33. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.77. The company has a 50 day moving average of $2.05 and a two-hundred day moving average of $2.03.

Gritstone bio (NASDAQ:GRTSGet Free Report) last announced its earnings results on Tuesday, March 5th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.10. The company had revenue of $10.38 million during the quarter, compared to the consensus estimate of $4.80 million. Gritstone bio had a negative net margin of 847.24% and a negative return on equity of 147.22%.

Institutional Investors Weigh In On Gritstone bio

Several institutional investors and hedge funds have recently made changes to their positions in GRTS. JPMorgan Chase & Co. lifted its stake in shares of Gritstone bio by 7.4% during the first quarter. JPMorgan Chase & Co. now owns 66,140 shares of the company’s stock worth $273,000 after buying an additional 4,557 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Gritstone bio by 22,727.3% during the first quarter. PNC Financial Services Group Inc. now owns 10,044 shares of the company’s stock worth $41,000 after buying an additional 10,000 shares during the period. BlackRock Inc. lifted its stake in shares of Gritstone bio by 2.7% during the first quarter. BlackRock Inc. now owns 3,893,393 shares of the company’s stock worth $16,041,000 after buying an additional 101,960 shares during the period. Vanguard Group Inc. raised its holdings in shares of Gritstone bio by 0.9% during the first quarter. Vanguard Group Inc. now owns 2,734,707 shares of the company’s stock worth $11,267,000 after purchasing an additional 23,437 shares during the last quarter. Finally, Ergoteles LLC purchased a new position in shares of Gritstone bio during the first quarter worth $128,000. 48.46% of the stock is currently owned by institutional investors and hedge funds.

About Gritstone bio

(Get Free Report)

Gritstone bio, Inc, a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors.

See Also

Earnings History and Estimates for Gritstone bio (NASDAQ:GRTS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Gritstone bio, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Gritstone bio wasn’t on the list.

While Gritstone bio currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in 2024 Cover

Click the link below and we’ll send you MarketBeat’s list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Source link

Check Also

Equities Analysts Offer Predictions for Chubb Limited’s FY2024 Earnings (NYSE:CB)

Chubb Limited (NYSE:CB – Free Report) – Stock analysts at Zacks Research decreased their FY2024 …

Leave a Reply

Your email address will not be published. Required fields are marked *